Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ISIS-329993
- Development stage
- Phase 2
- Lead developer
- Ionis Pharmaceuticals
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
ISIS-329993 is a **second-generation antisense oligonucleotide** developed to inhibit the production of *C-reactive protein* (CRP) by binding specifically to CRP mRNA and preventing its translation. CRP is a marker and mediator of inflammation implicated in several diseases, including cardiovascular and autoimmune conditions. ISIS-329993 was primarily investigated in phase 2 clinical trials for its ability to lower CRP levels in patients with paroxysmal atrial fibrillation and rheumatoid arthritis. While ISIS-329993 led to dose-dependent reductions in CRP, trials did not show an improvement in disease activity or symptom burden in these settings. The drug demonstrated favorable safety and tolerability profiles but was ultimately **discontinued in clinical development**[1][2][3][7].
- Brand names
- ISIS-329993ISIS329993ISIS 329993
- Other names
- ISIS-CRPRxISIS-CRP
Beyond the preview
Go deeper on ISIS-329993.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ISIS-329993.